Get the Stockscreener App
16.73
16.56%
-3.32
After Hours:
17.00
0.27
+1.61%
Prothena Corporation Plc stock is traded at $16.73, with a volume of 3.09M.
It is down -16.56% in the last 24 hours and down -24.88% over the past month.
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
See More
Previous Close:
$20.05
Open:
$19.96
24h Volume:
3.09M
Relative Volume:
7.47
Market Cap:
$874.11M
Revenue:
$217.25M
Net Income/Loss:
$-50.92M
P/E Ratio:
-11.78
EPS:
-1.42
Net Cash Flow:
$-100.85M
1W Performance:
-23.95%
1M Performance:
-24.88%
6M Performance:
-32.46%
1Y Performance:
-65.33%
1-Day Range:
$15.52
$19.96
1-Week Range:
$15.52
$22.25
52-Week Range:
$15.52
$55.89
Prothena Corporation Plc Stock (PRTA) Company Profile
Name
Prothena Corporation Plc
Sector
Industry
Phone
011-353-1-236-2500
Address
77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2
Prothena Corporation Plc Stock (PRTA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Apr-24-23 | Initiated | SVB Securities | Outperform |
| Jan-27-23 | Initiated | Piper Sandler | Overweight |
| Nov-04-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-28-22 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-19-21 | Initiated | JMP Securities | Mkt Outperform |
| Jun-18-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-08-21 | Reiterated | Oppenheimer | Outperform |
| May-26-21 | Initiated | Citigroup | Buy |
| Feb-26-21 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-12-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-02-21 | Upgrade | BTIG Research | Neutral → Buy |
| Dec-07-20 | Initiated | H.C. Wainwright | Buy |
| Jul-09-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-19-19 | Upgrade | Evercore ISI | In-line → Outperform |
| May-21-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Apr-23-18 | Downgrade | Jefferies | Buy → Hold |
| Apr-05-18 | Reiterated | Barclays | Overweight |
| Nov-20-17 | Downgrade | Wedbush | Outperform → Neutral |
| Sep-29-17 | Reiterated | BTIG Research | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-11-17 | Initiated | Jefferies | Buy |
| Apr-12-17 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-12-17 | Initiated | Piper Jaffray | Overweight |
| Mar-02-17 | Initiated | Instinet | Buy |
| Dec-21-16 | Initiated | SunTrust | Buy |
| Nov-03-16 | Initiated | Deutsche Bank | Buy |
| Aug-04-16 | Reiterated | Barclays | Overweight |
| May-13-16 | Initiated | Barclays | Overweight |
| Feb-19-16 | Reiterated | Wedbush | Outperform |
| Jan-21-16 | Initiated | Credit Suisse | Outperform |
View All
Prothena Corporation Plc Stock (PRTA) Latest News
Prothena (NASDAQ:PRTA) Hits New 52-Week Low at $18.40 - MarketBeat
Prothena (NASDAQ:PRTA) Earns Overweight Rating from Cantor Fitzgerald - MarketBeat
Systematic Financial Management LP Purchases 39,771 Shares of Prothena Co. plc (NASDAQ:PRTA) - MarketBeat
Prothena's SWOT analysis: biotech stock faces high-risk, high-reward pipeline - Investing.com
Prothena Announces Leadership Team Updates - StockTitan
Prothena names Chad Swanson as new Chief Development Officer - Investing.com
Profund Advisors LLC Has $373,000 Stock Position in Prothena Co. plc (NASDAQ:PRTA) - Defense World
Profund Advisors LLC Has $373,000 Stock Position in Prothena Co. plc (NASDAQ:PRTA) - MarketBeat
Armistice Capital LLC Increases Stock Position in Prothena Co. plc (NASDAQ:PRTA) - MarketBeat
Renaissance Technologies LLC Reduces Stock Position in Prothena Co. plc (NASDAQ:PRTA) - Defense World
Prologis Inc. stock rises Tuesday, still underperforms market - MarketWatch
Prothena Co. plc (NASDAQ:PRTA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Petratherm Ltd Reports Key Shareholder Changes - TipRanks
Petra Diamonds Adjusts Strategy Amidst Market Challenges - TipRanks
ProSiebenSat.1 Media (OTCMKTS:PBSFY) Shares Up 8.7% - Defense World
Praxis Precision Medicines (NASDAQ:PRAX) Trading Down 7.9% - MarketBeat
Psyence Biomedical Ltd. (PBM) Stock: Uncovering 52-Week Market Trends - The InvestChronicle
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 4% - MarketBeat
A look into Prothena Corporation plc (PRTA)’s deeper side - SETE News
Edge Capital Group LLC Has $506,000 Holdings in Palantir Technologies Inc. (NYSE:PLTR) - Defense World
Tri Locum Partners LP Trims Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - MarketBeat
Federated Hermes Inc. Has $827,000 Position in Proto Labs, Inc. (NYSE:PRLB) - Defense World
Palantir Technologies Inc. (NYSE:PLTR) Shares Sold by Brighton Jones LLC - Defense World
43,861 Shares in Prothena Co. plc (NASDAQ:PRTA) Bought by Federated Hermes Inc. - MarketBeat
Prothena Co. plc (NASDAQ:PRTA) Shares Acquired by Rhumbline Advisers - Defense World
Where are the Opportunities in (PRTA) - Stock Traders Daily
Just the Facts: Provaris Energy submits offer for hydrogen tank production cell at Fiskå Facility - Proactive Investors Australia
Provaris Energy submits offer to acquire prototype hydrogen tank production cells - Proactive Investors Australia
Jefferies lowers Progyny price target to $24, calls selloff ‘excessive’ - TipRanks
Market Watch Highlights: Prothena Corporation plc (PRTA) Ends on an Downturn Note at 21.48 - The Dwinnex
Prothena Corporation plc (PRTA) deserves closer scrutiny - US Post News
Progyny Stock Faces Its Biggest Drop Ever After Losing a Major Client. Why These Analysts Like the Stock. - Barron's
Prothena Co. plc (NASDAQ:PRTA) Shares Sold by Arizona State Retirement System - Defense World
PPL-001 gets US orphan drug designation for Friedreich’s ataxia - BioWorld Online
Alert: $1 Billion Palantir Insider Selling - Baystreet.ca
Headlands Technologies LLC Sells 2,206 Shares of Prothena Co. plc (NASDAQ:PRTA) - Defense World
Bank of New York Mellon Corp Acquires 19,578 Shares of Prothena Co. plc (NASDAQ:PRTA) - Defense World
Investors bid Prothena (NASDAQ:PRTA) up US$96m despite increasing losses YoY, taking five-year CAGR to 21% - Simply Wall St
Prothena Co. plc (NASDAQ:PRTA) Shares Sold by TD Asset Management Inc - Defense World
Prothena (NASDAQ:PRTA) Stock Price Up 7.4% - MarketBeat
Learn to Evaluate (PRTA) using the Charts - Stock Traders Daily
Zurcher Kantonalbank Zurich Cantonalbank Acquires 1,186 Shares of Prothena Co. plc (NASDAQ:PRTA) - Defense World
Prothena Co. plc (NASDAQ:PRTA) Shares Purchased by Signaturefd LLC - Defense World
Prothena to Participate in Upcoming Healthcare Conferences - StockTitan
Prothena to Participate in Upcoming Healthcare Conferences - Business Wire
Prothena Co. plc (NASDAQ:PRTA) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Prothena Co. plc (NASDAQ:PRTA) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Prothena (NASDAQ:PRTA) Stock Price Passes Below Two Hundred Day Moving Average of $23.08 - MarketBeat
Prothena (NASDAQ:PRTA) Share Price Crosses Below 200-Day Moving Average of $23.08 - Defense World
What Makes Prothena (PRTA) a New Buy Stock - Yahoo Finance
Prothena Corporation plc (PTRA): Positioning Among Top Debt-Free Stocks - Insider Monkey
Prothena Corporation Plc Stock (PRTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Prothena Corporation Plc Stock (PRTA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Walker Karin L | Chief Accounting Officer |
Jan 24 '24 |
Sale |
34.00 |
5,000 |
170,000 |
0 |
| Walker Karin L | Chief Accounting Officer |
Dec 20 '23 |
Option Exercise |
13.53 |
5,000 |
67,650 |
5,000 |
| Walker Karin L | Chief Accounting Officer |
Dec 20 '23 |
Sale |
37.19 |
5,000 |
185,952 |
0 |
| Walker Karin L | Chief Accounting Officer |
Nov 30 '23 |
Option Exercise |
13.53 |
5,000 |
67,650 |
5,000 |
| Walker Karin L | Chief Accounting Officer |
Nov 30 '23 |
Sale |
34.00 |
5,000 |
170,000 |
0 |
| Walker Karin L | Chief Accounting Officer |
Oct 25 '23 |
Option Exercise |
13.53 |
5,000 |
67,650 |
5,000 |
| Walker Karin L | Chief Accounting Officer |
Oct 25 '23 |
Sale |
41.04 |
5,000 |
205,191 |
0 |
| Smith Brandon S. | Chief Operating Officer |
Oct 11 '23 |
Option Exercise |
11.12 |
4,000 |
44,480 |
4,000 |
| Smith Brandon S. | Chief Operating Officer |
Oct 11 '23 |
Sale |
46.75 |
4,000 |
186,985 |
0 |
| Karp Carol D. | Chief Regulatory Officer |
Oct 04 '23 |
Option Exercise |
12.15 |
5,000 |
60,750 |
5,000 |
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):